This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology (ALGN) Q3 Earnings Lag Estimates, Margins Drop
by Zacks Equity Research
The volatility surrounding inflationary pressure, weaker consumer confidence and the lingering impacts of COVID-19 shutdowns continue to pose challenges for Align Technology (ALGN).
CONMED (CNMD) Down on In-Line Q3 Earnings & Lower 2022 View
by Zacks Equity Research
CONMED's (CNMD) adjusted third-quarter earnings reflect strong segmental performance. Unfavorable currency movement hurt sales growth. Inflationary or supply chain challenges hurt gross margin.
The Zacks Analyst Blog Highlights The Home Depot, Elevance Health, BP, Gilead Sciences and ServiceNow
by Zacks Equity Research
The Home Depot, Elevance Health, BP, Gilead Sciences and ServiceNow are part of the Zacks top Analyst Blog.
Elevance Health, Inc. (ELV) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Elevance Health (ELV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's How Much a $1000 Investment in Elevance Health Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
West Pharmaceutical (WST) Q3 Earnings Miss, FY22 View Revised
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.
Top Stock Reports for The Home Depot, Elevance Health & BP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Elevance Health Inc. (ELV) and BP p.l.c. (BP).
Thermo Fisher (TMO) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Robust demand for Thermo Fisher's (TMO) laboratory products and biopharma services buoys optimism. However, lower Life Sciences Solutions segment revenues in the third quarter disappoint.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Ideas feature highlights: Elevance Health, McKesson and Humana
by Zacks Equity Research
Elevance Health, McKesson and Humana are part of Zacks Investment Ideas article.
Centene (CNC) Q3 Earnings Top on Medicaid Arm, Revenues Rise Y/Y
by Zacks Equity Research
Centene's (CNC) third-quarter results reflect solid membership growth within its Medicaid and Medicare businesses. Management currently expects adjusted EPS within $5.65-$5.75 for 2022.
3 Top-Ranked Medical Stocks Lapping the S&P 500
by Derek Lewis
All three stocks are up double-digit percentages in 2022, leaving the S&P 500's performance in the dust. With the stocks carrying favorable near-term earnings outlooks, the run could easily continue.
HCA Healthcare (HCA) Q3 Earnings Beat, Revenues Decline Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter results reflect a slight dip in expenses but lower revenues resulting from the havoc wreaked by Hurricane Ian on its Florida facilities.
Here is Why Growth Investors Should Buy Elevance Health (ELV) Now
by Zacks Equity Research
Elevance Health (ELV) could produce exceptional returns because of its solid growth attributes.
ELV or PGNY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. PGNY: Which Stock Is the Better Value Option?
Company News for Oct 20, 2022
by Zacks Equity Research
Companies in The News Are: TRV,ALLY,BMI,ELV
Elevance Health (ELV) Beats on Q3 Earnings, Ups '22 EPS View
by Zacks Equity Research
Elevance Health (ELV) is witnessing rapid growth in medical enrollment and expects to keep doing so.
Elevance Health (ELV) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 6.06% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Elevance Health (ELV) to Post Q3 Earnings: A Beat in the Cards?
by Zacks Equity Research
Elevance Health's (ELV) third-quarter results are likely to reflect improved premiums and net investment income.
Will Elevance Health (ELV) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Elevance Health (ELV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Humana (HUM) Brings Affordable MA Plan to U.S. Veterans
by Zacks Equity Research
Humana (HUM) ties up with USAA Life to develop a Medicare Advantage plan that transcends the VA system to fetch added healthcare benefits for veterans.
Elevance Health's (ELV) Low-Cost MA Plans to Widen U.S. Base
by Zacks Equity Research
Elevance Health (ELV) devises suitable Medicare Advantage plans containing supplemental benefits, which consumers can avail in the 2023 Annual Enrollment Period.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks.com featured highlights include BJ's Wholesale Club, Elevance Health, MGIC Investment, Mercer International and RCM Technologies
by Zacks Equity Research
BJ's Wholesale Club, Elevance Health, MGIC Investment, Mercer International and RCM Technologies are part of Zacks Screen of the Week article.
Encompass Health's (EHC) Future Hospital to Serve Pennsylvania
by Zacks Equity Research
Encompass Health (EHC) decides to develop a 50-bed inpatient rehabilitation hospital in Pennsylvania to better serve the rehabilitative needs of the local communities.